MH & Associates Securities Management Corp ADV Purchases Shares of 138,731 Teva Pharmaceutical Industries Ltd. $TEVA

MH & Associates Securities Management Corp ADV purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 138,731 shares of the company’s stock, valued at approximately $4,330,000. Teva Pharmaceutical Industries makes up approximately 3.5% of MH & Associates Securities Management Corp ADV’s portfolio, making the stock its 4th largest holding.

Other institutional investors have also recently bought and sold shares of the company. Grove Bank & Trust lifted its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. Cromwell Holdings LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. Rothschild Investment LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after purchasing an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 257.1% in the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after purchasing an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $30.50 on Thursday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35. The firm has a market capitalization of $35.07 billion, a PE ratio of 25.42, a PEG ratio of 10.13 and a beta of 0.76. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The business’s 50-day simple moving average is $31.99 and its 200 day simple moving average is $28.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries’s revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on TEVA shares. Piper Sandler restated an “overweight” rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Finally, Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the sale, the insider directly owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. This represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Richard Daniell sold 17,295 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the sale, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 920,901 shares of company stock valued at $30,056,789. 0.49% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.